Περίληψη:
Purpose: To determine the efficacy and tolerance of single-agent
docetaxel and granulocyte colony-stimulating factor in patients with
advanced pancreatic cancer.
Patients and Methods: Thirty-three chemotherapy-naive patients (median
age, 65 years) with histologically confirmed pancreatic cancer were
treated, after appropriate premedication, with docetaxel (100 mg/m(2))
and granulocyte colony-stimulating factor(150 mu g/m(2)/d subcutaneously
days 2 through 10) every 3 weeks. World Health Organization performance
status was 0 to 1 in 28 patients (85%) and 2 in 5 patients (15%),
Twenty-nine patients had stage III and IV disease.
Results: One complete response (3%) and one partial response (3%) were
observed far an overall response rate of 6% (95% confidence interval,
2.1% to 14.2%), Nineteen patients (58%) had stable disease and
12(36%) had progressive disease. The duration of the two objective
responses was 10 and 28 weeks, and the median time to tumor progression
was 20 weeks. The median overall survival was 36 weeks. The actuarial
I-year survival was 36.4%, The performance status improved in seven of
21 assessable patients (24%) and pain improved in 14 of 21 (67%)
assessable patients; five patients (29%) experienced weight gain during
treatment. Disease-related asthenia, anorexia, vomiting, and diarrhea
improved in 29%, 15%, 67%, and 47% of the assessable patients,
respectively. Serum concentrations of CA 19-9 were decreased by more
than 50% in seven patients (35%). Grade 3 and 4 neutropenia occurred
in four patients (12%) and eight patients (24%), respectively, with
two episodes of febrile neutropenia. There were no treatment-related
deaths. Grade 3/4 asthenia occurred in three patients.
Conclusion: Although docetaxel teas a marginal objective activity in
pancreatic cancer, it seems to have an important effect on tumor growth
control, conferring a clinical benefit, (C) 1999 by American Society of
Clinical Oncology.
Συγγραφείς:
Androulakis, N
Kourousis, C
Dimopoulos, MA
Samelis, G and
Kakolyris, S
Tsavaris, N
Genatas, K
Aravantinos, G and
Papadimitriou, C
Karabekios, S
Stathopoulos, GP
Georgoulias,
V
